Bicocca Open Archive

Logo unimib boa
CAIROLI, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 15.900
NA - Nord America 7.592
EU - Europa 6.015
SA - Sud America 2.119
AF - Africa 317
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 2
Totale 31.973
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.333
SG - Singapore 5.821
CN - Cina 3.238
HK - Hong Kong 2.878
RU - Federazione Russa 1.888
BR - Brasile 1.672
VN - Vietnam 1.563
IT - Italia 1.365
IE - Irlanda 899
KR - Corea 761
FR - Francia 375
DE - Germania 346
IN - India 328
ID - Indonesia 247
GB - Regno Unito 238
SE - Svezia 200
FI - Finlandia 170
BD - Bangladesh 165
AR - Argentina 164
IQ - Iraq 148
TR - Turchia 115
MX - Messico 103
NL - Olanda 103
PK - Pakistan 99
ZA - Sudafrica 99
CA - Canada 96
AT - Austria 84
EC - Ecuador 83
UA - Ucraina 79
PH - Filippine 73
ES - Italia 71
SA - Arabia Saudita 71
JP - Giappone 59
UZ - Uzbekistan 51
CO - Colombia 50
VE - Venezuela 48
MA - Marocco 45
TN - Tunisia 36
MY - Malesia 32
CL - Cile 31
EG - Egitto 31
JO - Giordania 30
KE - Kenya 30
PL - Polonia 30
AU - Australia 25
CH - Svizzera 24
PE - Perù 24
PY - Paraguay 23
AZ - Azerbaigian 20
ET - Etiopia 20
KZ - Kazakistan 19
NP - Nepal 19
LB - Libano 18
JM - Giamaica 16
AE - Emirati Arabi Uniti 15
DZ - Algeria 15
TH - Thailandia 15
BE - Belgio 14
IR - Iran 14
OM - Oman 14
TW - Taiwan 14
AL - Albania 13
LT - Lituania 13
IL - Israele 12
CZ - Repubblica Ceca 11
DO - Repubblica Dominicana 11
BO - Bolivia 10
DK - Danimarca 10
GE - Georgia 10
GR - Grecia 10
PS - Palestinian Territory 10
HR - Croazia 9
HU - Ungheria 9
PT - Portogallo 9
UY - Uruguay 9
AO - Angola 8
RO - Romania 8
BH - Bahrain 7
LY - Libia 7
TT - Trinidad e Tobago 7
BG - Bulgaria 6
CR - Costa Rica 6
NO - Norvegia 6
PA - Panama 6
SY - Repubblica araba siriana 6
KW - Kuwait 5
RS - Serbia 5
SN - Senegal 5
BY - Bielorussia 4
GT - Guatemala 4
KG - Kirghizistan 4
NI - Nicaragua 4
QA - Qatar 4
BA - Bosnia-Erzegovina 3
HN - Honduras 3
NG - Nigeria 3
UG - Uganda 3
AM - Armenia 2
BN - Brunei Darussalam 2
CI - Costa d'Avorio 2
Totale 31.923
Salva come PNG Salva come JPEG
Città #
Singapore 3.214
Hong Kong 2.862
Hefei 1.391
San Jose 1.206
Dublin 848
Seoul 745
Ashburn 716
Ho Chi Minh City 480
New York 461
The Dalles 455
Santa Clara 441
Chicago 420
Hanoi 391
Milan 355
Lauterbourg 281
Los Angeles 275
Dallas 215
Beijing 197
Moscow 195
Buffalo 187
Jakarta 183
São Paulo 167
Ann Arbor 125
Helsinki 117
Frankfurt am Main 116
Nuremberg 112
Turin 92
Rome 85
Council Bluffs 84
Shanghai 75
Seattle 69
Haiphong 67
Da Nang 59
Baghdad 56
Rio de Janeiro 50
London 47
Fairfield 46
Lahore 45
Desio 43
Chandler 42
Salt Lake City 42
Tashkent 41
Amsterdam 39
Orem 39
Boardman 38
Houston 37
Johannesburg 36
Munich 36
Tokyo 35
Vienna 35
Tampa 34
Belo Horizonte 33
Biên Hòa 33
Mumbai 33
Dhaka 32
Phoenix 32
Guangzhou 31
Montreal 31
Porto Alegre 30
Washington 30
Amman 29
Chennai 29
Curitiba 29
Lappeenranta 29
Brasília 28
Atlanta 27
Wilmington 27
Ha Long 26
Quito 26
Riyadh 26
Istanbul 25
New Delhi 25
Jeddah 24
Nairobi 24
Brooklyn 23
Toronto 23
Bologna 22
Can Tho 22
Guayaquil 22
Jacksonville 22
San Francisco 22
Warsaw 22
Ankara 21
Boston 21
Hải Dương 21
Naples 21
Salvador 21
Caracas 20
Miami 20
Princeton 20
Changsha 19
Delhi 19
Hyderabad 19
Kent 19
Madrid 19
Mexico City 19
Paris 19
Redondo Beach 19
Addis Ababa 18
Campinas 18
Totale 18.617
Salva come PNG Salva come JPEG
Nome #
Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) 462
Assessing eligibility for treatment in acute myeloid leukemia in 2023 366
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 337
The role of quantitative polymerase chain reaction in the management of follicular lymphoma patients 264
Lymphoma’s last therapeutic option: Freeze it! 261
Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients 254
Advances in the understanding of molecular genetics and therapy ofRichter transformation in chronic lymphocytic leukemia 240
Cerebral Infectious Opportunistic Lesions in a Patient with Acute Myeloid Leukaemia: The Challenge of Diagnosis and Clinical Management 234
Communicating the diagnosis of a hematological neoplastic disease to patients’ minor children: a multicenter prospective study 233
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 226
RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia 223
Impact of serial echocardiography in the management of primary cardiac lymphoma 218
Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical Trial 199
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi 195
KIT activating mutations: Incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication 190
Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study 189
Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3 187
A phase I/IIa clinical trial of autologous hematopoietic stem cell transplantation in amyotrophic lateral sclerosis 184
Pirtobrutinib is an Effective Salvage Treatment After Ibrutinib in Bing–Neel Syndrome 173
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial 171
Effectiveness and Tolerability of Dual Antiviral Therapy in Immunosuppressed Patients with Protracted SARS-CoV-2 Infection 168
Fasting and Diet: Overview in Chronic Lymphocytic Leukemia 168
Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination.—Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda 168
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 166
Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review 162
Impaired survival of patients with non donor-specific anti-HLA antibodies before HLA-mismatched allogeneic stem cell transplantation 161
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapy 158
Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience 157
Exploring the administrative burden faced by hematologists: a comprehensive study in Italy 151
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities 151
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial 151
Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial 151
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 148
A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice 147
Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy? 143
"Efficient Strategies for the Reuse of Surgical and FFP2/ KN95 Face Masks during the COVID-19 Pandemic: Home-Made and Ecological Choices for the Community" 142
Use of Sorafenib in FLT3-Mutant Myeloid Sarcoma: A Case Report 139
In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation 134
Bone Marrow CD34+/lin− Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subjects 134
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 134
Myeloma’s multiple morphologies 133
Transcriptomic Signature of a Patient with Chronic Lymphocytic Leukemia Exhibiting Profound Fluctuations in the Lymphocytosis during Nutrition and Prolonged Fasting Periods 129
Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) 128
Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients 126
Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome 124
DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma 124
Intrahospital COVID-19 infection outbreak management: Keep calm and carry on 124
IN ADULT ACUTE MYELOID LEUKEMIA (AML) PERIPHERAL BLOOD MEASURABLE RESIDUAL DISEASE (MRD) BY FLOW CYTOMETRY (FC) IS FEASIBLE AND IS PROGNOSTICALLY RELEVANT 123
Saccharomyces cerevisiae fungemia with granulomas in the bone marrow in a patient undergoing BMT 122
A Nine-Gene Expression Signature Distinguished a Patient with Chronic Lymphocytic Leukemia Who Underwent Prolonged Periodic Fasting 122
Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial 122
Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy 122
Occurrence of L1M Elements in Chromosomal Rearrangements Associated to Chronic Myeloid Leukemia (CML): Insights from Patient-Specific Breakpoints Characterization 121
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 119
Hypoplasia of the Spleen: Rare and Puzzling 119
Cordycepin (3′dA) Induces Cell Death of AC133+ Leukemia Cells via Re-Expression of WIF1 and Down-Modulation of MYC 119
How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia 119
Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study 119
Plasma cell-directed therapy and anti-HLA antibody production: A successful combination? 118
Dual antiviral therapy in haematological patients with protracted SARS-CoV-2 infection 118
A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma 116
MIS-A: Beware of non-lymphoma 116
A novel start-loss mutation of the SH2B3 gene in a family with myeloproliferative neoplasms 115
Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol 115
c-kit activating mutations and mast cell proliferation in human leukemia [4] 115
VENETOCLAX IN MULTI-RELAPSED MANTLE CELL LYMPHOMA PATIENTS: A REAL-LIFE MULTICENTRIC EXPERIENCE 114
Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma 114
Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an "Old-fashioned" Drug be Effective? 113
Clinical Impact of Graft Cryopreservation on Allogeneic Stem Cell Transplantation: An Italian, Registry-Based Study on Behalf of the “Gruppo Italiano Per Il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare” (GITMO) 112
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 111
Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: Results of an Italian multicenter study 111
Use of Plerixafor in Poor Mobilizer Patients with Myeloma and Lymphoma: Clonogenic Capacity and Engraftment Data 108
A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis 108
Clinical management of peripherally inserted central catheters compared to conventional central venous catheters in patients with hematological malignancies: A large multicenter study of the REL GROUP (Rete Ematologica Lombarda - Lombardy Hematologic Network, Italy) 108
Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 108
A phase I/II study of NMS-03592088, a FLT3, KIT and CSF1R inhibitor, in patients with relapsed or refractory AML or CMML 105
PROGNOSTIC CORRELATION OF CELL-OF-ORIGIN AND MYC, BCL-2 AND BCL-6 STATUS IN HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS 104
Multidimensional Results and Reflections on CAR-T: The Italian Evidence 104
Response of steroid-refractory chronic graft-versus-host disease to extracorporeal photopheresis correlates with the dose of CD3+ lymphocytes harvested during early treatment cycles 102
Prognostic impact of C-KIT mutations in Core Binding Factor-Leukemia 102
FZD6 triggers Wnt–signalling driven by WNT10BIVS1 expression and highlights new targets in T-cell acute lymphoblastic leukemia 101
RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS OF THE AML1310 TRIAL OF THE GIMEMA GROUP 100
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 100
PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation 100
A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS 100
Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects 100
Treatment of elderly patients with acute promyelocytic leukemia: A real life experience of the “rete ematologica lombarda” 100
Prognostic impact of immunohistochemical p53 expression in bone marrow biopsy in higher risk MDS: A pilot study 99
Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment 99
IDENTIFICAZIONE DI MIRNA E GENI TARGET NELL’ANALISI TRASCRITTOMICA DELLE CELLULE CD34+/LIN- DI PAZIENTI CON LEUCEMIA MIELOIDE CRONICA IN FASE CRONICA DOPO 12 MESI DI TERAPIA CON NILOTINIB 99
Prognostic significance of CD33, CD34 and CD117 expression on bone marrow blasts of patients with Myelodysplastic syndromes 99
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV 99
Arg expression studied in normal human leukocytes and in leukemic cells by RT-PCR 99
"MOLTO", A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II CLINICAL TRIAL ON VENETOCLAX, ATEZOLIZUMAB, OBINUTUZUMAB (AVO) COMBINATION IN RICHTER TRANSFORMATION: SAFETY INTERIM ANALYSIS 98
Duvelisib for the treatment of chronic lymphocytic leukemia 98
A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Extensively Studied by Flow Cytometry and Immunohistochemistry 98
VERY LONG-TERM RESULTS OF ALL-TRANS RETINOIC ACID AND ARSENIC TRIOXIDE IN NON-HIGH RISK ACUTE PROMYELOCYTIC LEUKEMIA: LATEST UPDATE OF THE ITALIAN-GERMAN APL0406 RANDOMIZED TRIAL 98
Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results 98
Detection by polymerase chain reaction of BCR/ ABL transcripts in myeloproliferative diseases at time of diagnosis and for monitoring chronic myelogenous leukaemia patients after bone marrow transplantation 97
Complications at insertion of untunnelled central venous catheters (UCVCs) in leukemic patients at a high risk of hemorrhage 97
Totale 14.470
Salva come PNG Salva come JPEG
Categoria #
all - tutte 132.337
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 132.337
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202111 0 0 0 0 0 0 0 0 0 0 3 8
2021/2022121 6 3 15 7 11 10 2 14 7 8 12 26
2022/20231.417 27 57 11 13 9 26 0 151 58 921 64 80
2023/20243.794 57 115 139 106 515 840 653 200 657 104 76 332
2024/20259.731 545 1.184 457 439 783 295 687 221 844 1.048 1.035 2.193
2025/202617.588 2.037 2.311 1.568 2.487 1.507 934 2.639 904 1.528 1.438 235 0
Totale 33.002